美多芭联合恩他卡朋治疗对帕金森病患者血浆同型半胱氨酸水平的影响

Effect of madopar combined with entacapone administration on plasma homocysteine level in patients with Parkinson's disease

目的探讨美多芭联合恩他卡朋治疗对帕金森病(PD)患者血浆同型半胱氨酸(Hcy)水平的影响。方法选取30名健康体检者作为对照组,20例未服用过左旋多巴(LD)制剂的PD患者为未服药组,63例美多芭治疗的PD患者为美多芭组,49例美多芭联合恩他卡朋治疗的PD患者为联合组。检测患者外周血中的LD稳态峰浓度并进行统一PD评分量表Ⅲ(UPDRSⅢ)的评分。检测所有研究对象的血浆Hcy水平。结果联合组患者LD血浆浓度明显高于美多芭组(P<0.05)。美多芭组及联合组患者UPDRSⅢ评分均明显低于未服药组(均P<0.05)。与对照组比较,未服药组、美多芭组及联合组患者血浆Hcy水平均明显升高(均P<0.05);且美多芭组患者血浆Hcy水平明显高于未服药组及联合组(均P<0.05)。结论美多芭联合恩他卡朋能显著降低PD患者血浆Hcy水平,对PD治疗有积极意义。

Objective To investigate the effect of madopar combined with entacapone administration on plasma homocystein（ Hcy） level in patients with Parkinson＇s disease（ PD）. Methods Thirty healthy person were selected as a control group,20 PD subjects with no levodopa（ LD） taking were as no treatment group,63 subjects with madopar were as madopar group and 49 subjects with madopar combining entacapone were as combination group.Meanwhile levodopa concentration in peripheral blood and Unified PD Rating Scale Ⅲ（ UPDRS Ⅲ） score were measured. The plasma Hcy levels of all the researchers were detected. Results The L-dopa concentration in plasma of combination group was statistically significantly higher than that of madopar group（ P〈0. 05）. The score of UPDRSⅢ scale of madopar group and combination group were significantly lower than that of madopar group（ all P〈0. 05）. Compared with control group,the Hcy concentration in non-treatment group,madopar group and combination group were significantly increased（ all P〈0. 05）. And the Hcy concentration in madopar group was significantly higher than those in none treatment group and combination group（ all P〈0. 05）. Conclusion Madopar combined with entacapone therapy can significantly reduce plasma Hcy levels in patients with PD,which may be beneficial to the treatment of PD.